Cerevance raised $47M in a Series B funding round led by Agent Capital, Bioluminescence Ventures, and Double Point Ventures to develop precision novel therapeutics for central nervous system diseases.
Amount Raised
$47 Million
Round Type
Series B
BostonBiotechnologyHealth CareTherapeuticsInvestors
Description
Cerevance announced an initial closing of its Series B-1 Extension financing round, adding $47 million to the $51 million previously raised, bringing the total Series B-1 raise to $98 million. The funding was led by Agent Capital, Bioluminescence Ventures, and Double Point Ventures, with participation from new investors MQB Partners and LifeRock Ventures and existing investors Gates Frontier, GV (Google Ventures), and Lightstone Ventures. The proceeds will support the upcoming Phase 3 clinical trial for CVN424, a first-in-class non-dopamine therapy for patients with Parkinson’s disease, and the advancement of a pipeline of novel treatments for other CNS disorders.
Quick answer
Cerevance raised $47 Million in a Series B round, dated April 29, 2024. Investors: GV, Lightstone Ventures, Gates Frontier, Life Rock Ventures, MQB Partners, Double Point Ventures, Bioluminescence Ventures and Agent Capital. Cerevance is based in Boston, Massachusetts, United States.
- How much did Cerevance raise?
- Cerevance raised $47 Million in a Series B round on April 29, 2024.
- Who invested in Cerevance?
- GV, Lightstone Ventures, Gates Frontier, Life Rock Ventures, MQB Partners, Double Point Ventures, Bioluminescence Ventures and Agent Capital are named as investors in this round.
- What does Cerevance do?
- Cerevance is focused on the development of treatments for central nervous system (CNS) disorders, with a focus on neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral..
- Where is Cerevance based and how big is it?
- Cerevance is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Cerevance?
- Fundz holds 1 contact at Cerevance. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Cerevance that raised within 45 days of this round, from Fundz verified event records.
- InduPro raised $85M (Series A) on June 13, 2024.
- Amber Therapeutics raised $100M (Series A) on June 10, 2024.
- Calidi Biotherapeutics raised $5.5M on June 3, 2024.
- Summit Therapeutics raised $200M on June 3, 2024.
- Aptose Biosciences raised $4.4M (Seed) on June 3, 2024.
- Radiomer Therapeutics raised an undisclosed amount (Pre-Seed) on May 29, 2024.
Who to call at Cerevance, and when
A new round usually means Cerevance is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Cerevance raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cerevance, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cerevance. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cerevance raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansCerevance raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.